Esperion Therapeutis.Inc. buy Piper Sandler
Start price
25.11.25
/
50%
€3.00
Target price
25.11.26
€7.81
Performance (%)
-7.70%
Price
10.08.26
€2.77
Summary
This prediction is currently active. With a performance of -7.70%, the BUY prediction by Piper_Sandler is trending in the wrong direction. This prediction currently runs until 25.11.26. The prediction end date can be changed by Piper_Sandler at any time. Piper_Sandler has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Esperion Therapeutis.Inc. | 0.000% | 0.000% |
| iShares Core DAX® | 0,18 % | 5,07 % |
| iShares Nasdaq 100 | -0,77 % | -2,08 % |
| iShares Nikkei 225® | 0,73 % | -3,35 % |
| iShares S&P 500 | -0,17 % | 0,90 % |
Comments by Piper_Sandler for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Esperion Therapeutics (NASDAQ:ESPR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $9.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat